Mammaprint breast cancer test validated in node positive tumors
Further to my articles on FDA approved Mammaprint, Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced that an independent international consortium has demonstrated the prognostic power of its MammaPrint breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint can accurately identify a low risk group of lymph node-positive breast cancer patients with an excellent survival, implications that will help doctors to decide the optimal treatment management.
Agendia will start offering MammaPrint to patients having 1-3 positive lymph nodes in Europe. These data will also be submitted to the U.S. Food and Drug Administration (FDA) for regulatory approval at a later date.
For Agendia’s full press release please click on:
http://www.agendia.com/en/Agendia/Press-Releases/Press-Release/32
Elaine Warburton
Related Stories
POSTED IN: FDA, General Genetics and Health, Genetic Future, Genetic Ingenuity, Genetic Testing, Genetics of Disease, Personalized Medicine, cancer
.gif)
Recent Comments